Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $14 to $18.
Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $14 to $18.